TARS

Company Overview — What Does Tarsus Pharmaceuticals, Inc. Do?

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Tarsus Pharmaceuticals, Inc. (TARS) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Bobak Azamian and employs approximately 50 people. With a market capitalization of $3.0B, TARS is one of the notable companies in the Healthcare sector.

Tarsus Pharmaceuticals, Inc. (TARS) Stock Rating — Reduce (April 2026)

As of April 2026, Tarsus Pharmaceuticals, Inc. receives a Reduce rating with a composite score of 36.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.TARS ranks #2,152 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Tarsus Pharmaceuticals, Inc. ranks #248 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TARS Stock Price and 52-Week Range

Tarsus Pharmaceuticals, Inc. (TARS) currently trades at $72.56. The stock gained $0.14 (0.2%) in the most recent trading session. The 52-week high for TARS is $85.25, which means the stock is currently trading -14.9% from its annual peak. The 52-week low is $38.51, putting the stock 88.4% above its annual trough. Recent trading volume was 384K shares, suggesting relatively thin trading activity.

Is TARS Overvalued or Undervalued? — Valuation Analysis

Tarsus Pharmaceuticals, Inc. (TARS) carries a value factor score of 32/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 8.52x, versus the sector average of 2.75x. The price-to-sales ratio is 8.41x, compared to 1.66x for the average Healthcare stock.

At current multiples, Tarsus Pharmaceuticals, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Tarsus Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

Tarsus Pharmaceuticals, Inc. (TARS) earns a quality factor score of 29/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -23.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -14.5% versus the sector average of -33.1%.

On a margin basis, Tarsus Pharmaceuticals, Inc. reports gross margins of 93.0%, compared to 71.5% for the sector. The operating margin is -29.9% (sector: -66.1%). Net profit margin stands at -27.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 190.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TARS Debt, Balance Sheet, and Financial Health

Tarsus Pharmaceuticals, Inc. has a debt-to-equity ratio of 21.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.85x, indicating strong short-term liquidity. Total debt on the balance sheet is $72M. Cash and equivalents stand at $113M.

TARS has a beta of 0.59, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Tarsus Pharmaceuticals, Inc. is 64/100, reflecting average volatility within the normal range for its sector.

Tarsus Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Tarsus Pharmaceuticals, Inc. reported revenue of $348M and earnings per share (EPS) of $-1.59. Net income for the quarter was $-81M. Gross margin was 93.0%. Operating income came in at $-88M.

In FY 2025, Tarsus Pharmaceuticals, Inc. reported revenue of $451M and earnings per share (EPS) of $-1.59. Net income for the quarter was $-66M. Revenue grew 146.7% year-over-year compared to FY 2024. Operating income came in at $-71M.

In Q3 2025, Tarsus Pharmaceuticals, Inc. reported revenue of $119M and earnings per share (EPS) of $-0.30. Net income for the quarter was $-13M. Revenue grew 146.7% year-over-year compared to Q3 2024. Operating income came in at $-15M.

In Q2 2025, Tarsus Pharmaceuticals, Inc. reported revenue of $103M and earnings per share (EPS) of $-0.48. Net income for the quarter was $-20M. Revenue grew 151.5% year-over-year compared to Q2 2024. Operating income came in at $-22M.

Over the past 8 quarters, Tarsus Pharmaceuticals, Inc. has demonstrated a growth trajectory, with revenue expanding from $41M to $348M. Investors analyzing TARS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TARS Dividend Yield and Income Analysis

Tarsus Pharmaceuticals, Inc. (TARS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TARS Momentum and Technical Analysis Profile

Tarsus Pharmaceuticals, Inc. (TARS) has a momentum factor score of 56/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 7/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

TARS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Tarsus Pharmaceuticals, Inc. (TARS) ranks #248 out of 838 stocks based on the Blank Capital composite score. This places TARS in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TARS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TARS vs S&P 500 (SPY) comparison to assess how Tarsus Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

TARS Next Earnings Date

No upcoming earnings date has been announced for Tarsus Pharmaceuticals, Inc. (TARS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TARS? — Investment Thesis Summary

The quantitative profile for Tarsus Pharmaceuticals, Inc. suggests caution. The quality score of 29/100 flags below-average profitability. The value score of 32/100 indicates premium valuation. Low volatility (stability score 64/100) reduces downside risk.

In summary, Tarsus Pharmaceuticals, Inc. (TARS) earns a Reduce rating with a composite score of 36.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TARS stock.

Related Resources for TARS Investors

Explore more research and tools: TARS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TARS head-to-head with peers: TARS vs AZN, TARS vs SLGL, TARS vs VMD.